The U.S. Food and Drug Administration has approved Regeneron's Dupixent (dupilumab) as an add-on maintenance treatment for ...

A rapid decline in lung function is linked to the development of chronic obstructive pulmonary disease (COPD) ...

The US Food and Drug Administration has approved dupilumab as an add-on maintenance therapy for adults whose chronic ...

Extrafine single inhaler triple therapy is effective among patients with COPD who were previously treated with multiple-inhaler triple therapy.

The global chronic disease management market size is estimated to be worth USD 5.57 billion in 2024 and is projected to reach ...

For people in the MetroWest region living with lung diseases such as chronic obstructive pulmonary disease (COPD), emphysema, ...

The following is a summary of “Vancomycin-resistant Enterococcus (VRE) Pneumonia in a Patient With Advanced Chronic ...

N-acetylcysteine (NAC) nebulizer therapy is effective and safe in the short-term (12 weeks) for reducing phlegm in COPD.

Dress for Success ...

Patients with asthma and COPD routinely switch from pressurized metered-dose inhalers (pMDIs) to dry powder inhalers (DPIs) and vice versa.

and airway remodeling associated with chronic obstructive pulmonary disease (COPD). Selective PDE4 inhibition is proposed to maximize the antiinflammatory effects of PDE inhibition while ...